• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Ultragenyx Pharmaceutical (RARE)

Common Shares
Sell: $20.07|Buy: $22.50|Change: 1.03 (4.81%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitatinggenetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated fromNorth America.

Address

60 Leveroni Court
Novato
CA
USA
94949

Telephone

+1 415 4838800

Website

https://www.ultragenyx.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Ultragenyx Pharmaceutical Inc Annual Report for 20262027-02-18T00:00:00
Ultragenyx Pharmaceutical Inc Fourth Quarter Earnings Conference Call for 20262027-02-12T17:00:00
Ultragenyx Pharmaceutical Inc Fourth Quarter Earnings Results for 20262027-02-12T00:00:00
Ultragenyx Pharmaceutical Inc Third Quarter Earnings Conference Call for 20262026-11-04T17:00:00
Ultragenyx Pharmaceutical Inc Third Quarter Earnings Results for 20262026-11-04T00:00:00
Ultragenyx Pharmaceutical Inc Second Quarter Earnings Conference Call for 20262026-08-05T17:00:00
Ultragenyx Pharmaceutical Inc Second Quarter Earnings Results for 20262026-08-05T00:00:00
Ultragenyx Pharmaceutical Inc Annual General Meeting for 20262026-05-15T09:00:00
Ultragenyx Pharmaceutical Inc First Quarter Earnings Conference Call for 20262026-05-06T17:00:00
Ultragenyx Pharmaceutical Inc First Quarter Earnings Results for 20262026-05-06T00:00:00

Previous key dates

NameKey Date
Leerink Partners Global Biopharma Conference2026-03-11T10:00:00
Barclays 28th Annual Global Healthcare Conference2026-03-10T12:00:00
46(th) Annual Cowen Healthcare Conference2026-03-02T13:50:00
Ultragenyx Pharmaceutical Inc Annual Report for 20252026-02-18T00:00:00
Ultragenyx Pharmaceutical Inc Fourth Quarter Earnings Conference Call for 20252026-02-12T17:00:00
Ultragenyx Pharmaceutical Inc Fourth Quarter Earnings Result for 20252026-02-12T00:00:00
44th Annual J.P. Morgan Healthcare Conference2026-01-12T10:30:00
8th Annual Evercore ISI Healthcare Conference2025-12-03T12:55:00
Citi’s 2025 Global Healthcare Conference2025-12-02T15:15:00
Ultragenyx Pharmaceutical Inc Third Quarter Earnings Conference Call for 20252025-11-04T17:00:00
Ultragenyx Pharmaceutical Inc Third Quarter Earnings Results for 20252025-11-04T00:00:00
Bank of America Global Healthcare Conference2025-09-23T10:35:00
Morgan Stanley 23rd Annual Global Healthcare Conference2025-09-09T16:05:00
Cantor Global Healthcare Conference 20252025-09-04T10:55:00
Ultragenyx Pharmaceutical Inc Second Quarter Earnings Conference Call for 20252025-08-05T17:00:00
Ultragenyx Pharmaceutical Inc Second Quarter Earnings Results for 20252025-08-05T00:00:00
Goldman Sachs 46th Annual Global Healthcare Conference2025-06-10T10:00:00
Ultragenyx Pharmaceutical Inc Annual General Meeting for 20252025-05-15T09:00:00
BofA Securities 2025 Healthcare Conference2025-05-13T11:00:00
Ultragenyx Pharmaceutical Inc First Quarter Earnings Conference Call for 20252025-05-06T17:00:00
Ultragenyx Pharmaceutical Inc First Quarter Earnings Result for 20252025-05-06T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.